Cervical intraepithelial neoplasia in women who had vaccination against HPV.
HPV
Cervical dysplasia
Human papillomavirus
Nonavalent vaccination
Vaccination
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
26
11
2018
revised:
14
03
2019
accepted:
29
07
2019
pubmed:
31
7
2019
medline:
4
12
2019
entrez:
31
7
2019
Statut:
ppublish
Résumé
To investigate the characteristics of women developing cervical intraepithelial neoplasia who had had a vaccination against human papillomavirus (HPV). A retrospective cohort study was carried out of women diagnosed with moderate or severe cervical dysplasia (CIN2+) in four Italian centers between 2015 and 2017. All women included had had previous bivalent or quadrivalent vaccination against HPV. The present study included 43 patients affected by CIN2+. The median age was 28 (range, 21-41) years. Ten (23.3%) patients did not have a diagnosis of specific HPV type(s) involved: high-risk HPV was detected in 7 (16.3%) women while HPV testing was negative in 3 (6.9%) women. Lesions related to HPV16 were found in two patients. HPV types covered by nonavalent vaccination were diagnosed in 27/33 (81.8%) women. HPV types not covered by nonavalent vaccination were diagnosed in 6 (18.2%) women. Co-infections are most commonly detected in women with HPVs other than those included in the nonavalent vaccination (P=0.024). Cervical dysplasia occurring after HPV vaccination is a rare condition. Theoretically, nonavalent vaccination should improve protection against more than 80% of HPV-related lesions compared to other vaccines.
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
233-237Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2019 International Federation of Gynecology and Obstetrics.
Références
Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40:187-193.
Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204.
Sand FL, Munk C, Frederiksen K, et al. Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types. Int J Cancer. 2019;144:1975-1982.
Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: A systematic review and meta-analysis. Am J Epidemiol. 2008;168:123-137.
Bogani G, Taverna F, Lombardo C, et al. Predicting Factors for High-Grade Cervical Dysplasia in Women With Low-Grade Cervical Cytology and Nonvisible Squamocolumnar Junction. Reprod Sci. 2019;26:44-48.
Bogani G, Leone Roberti Maggiore U, Signorelli M, et al. The role of human papillomavirus vaccines in cervical cancer: Prevention and treatment. Crit Rev Oncol Hematol. 2018;122:92-97.
Bogani G, Taverna F, Lombardo C, et al. Potential impact of introducing a nonavalent HPV vaccination. Int J Gynecol Obstet. 2018;142:338-342.
Bogani G, Ditto A, Martinelli F, et al. Artificial intelligence estimates the impact of human papillomavirus types in influencing the risk of cervical dysplasia recurrence: Progress toward a more personalized approach. Eur J Cancer Prev. 2019;28:81-86.
Bogani G, Taverna F, Lombardo C, et al. Retrospective study of the influence of HPV persistence on outcomes among women with high-risk HPV infections and negative cytology. Int J Gynecol Obstet. 2017;138:62-68.
International Agency for Research on Cancer, World Health Organization. Cervix cancer screening/IARC handbooks of cancer prevention. Vol 10. Lyon, France: International Agency for Research on Cancer; 2005.
Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;(5):CD009069.
Canfell K, Caruana M, Gebski V, et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. PLoS Med. 2017;14:e1002388.
Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016;16:1154-1168.
Sun M, Shen Y, Ren ML, Dong YM. Meta-analysis on the performance of p16/Ki-67 dual immunostaining in detecting high-grade cervical intraepithelial neoplasm. J Cancer Res Ther. 2018;14:S587-S593.
Shain AF, Wilbur DC, Stoler MH, Quade BJ, Kong CS. Test Characteristics of Specific p16 Clones in the Detection of High-grade Squamous Intraepithelial Lesions (HSIL). Int J Gynecol Pathol. 2018;37:82-87.